NMNH vs NMN: Is Reduced NMN Actually Better? (2026 Evidence Review)

What Is NMNH? The Basics of Reduced NMN

NMNH stands for dihydronicotinamide mononucleotide. It is the reduced form of NMN (nicotinamide mononucleotide), meaning it carries an additional hydrogen atom on its nicotinamide ring. This single chemical difference changes how the molecule enters the NAD+ synthesis pathway.

Standard NMN is the oxidized form. When your body converts NMN into NAD+, the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase) joins NMN with an ATP molecule to produce NAD+. NMNH takes a slightly different route: NMNAT converts NMNH into NADH (the reduced form of NAD+), which can then be oxidized to NAD+. NMNH may also be oxidized to NMN first, then follow the standard pathway. The net result is the same destination (NAD+), but NMNH potentially arrives there faster because it enters the pathway in a more energetically favorable state.

For context on what NMN is and how NAD+ works in the body, see our What Is NMN and What Is NAD+ guides.

The Preclinical Case for NMNH: What the Lab Data Shows

The foundational study on NMNH was published in 2021 by Liu and colleagues in the Journal of Proteome Research. The researchers developed a method to synthesize NMNH and then compared its NAD+-boosting ability against NMN in both cell culture and mice (Liu et al., 2021, PMID: 33793246).

The results were striking. In cell culture, NMNH increased intracellular NAD+ levels approximately 10-fold at concentrations where NMN only doubled them. NMNH also reached its peak NAD+ effect faster than NMN. In mice, NMNH injections raised blood NAD+ to substantially higher levels than equivalent NMN injections. The NMNH effect was also more sustained: NAD+ levels from NMN began declining after about 4 hours and returned to baseline by 20 hours, while NMNH maintained elevated NAD+ for at least 24 hours.

However, the same study found that NMNH also increased NADH levels (the reduced form of NAD+), suppressed glycolysis, inhibited the TCA cycle, and arrested cell growth in culture. These are not necessarily beneficial effects. Elevated NADH relative to NAD+ (a reduced NAD+/NADH ratio) has been associated with metabolic dysfunction in some contexts. The authors themselves noted that the biological implications of NMNH's effects on cellular metabolism require further investigation before therapeutic applications can be considered.

A 2026 study published in FASEB Journal by Vinten and colleagues extended this work by showing that reduced versus oxidized NAD+ precursors drive distinct transcriptomic responses, meaning they turn on different sets of genes (Vinten et al., 2026, PMID: 41701114). This finding suggests that NMNH and NMN are not simply different speeds of the same process but may have qualitatively different effects on cellular function.

Independent Confirmation: The Zapata-Pérez Study

A separate research group led by Zapata-Pérez and colleagues at the Hasso Plattner Institute of Digital Health independently confirmed NMNH's potency in a 2021 study published in FASEB Journal (Zapata-Pérez et al., 2021, PMID: 33724555). This team developed their own synthesis method for NMNH (independent of Liu's group) and tested it in both cell culture and mice.

Their findings aligned with Liu's results: NMNH increased NAD+ levels faster and to a greater extent than NMN or NR in mammalian cells. In mice, NMNH administration caused a rapid and sustained NAD+ surge in whole blood, with increased NAD+ levels detected in liver, kidney, and muscle tissue. The team also identified a new pathway for recycling reduced NAD+ precursors through NMNAT enzymes and proposed NMNH as having therapeutic potential for acute kidney injury, based on preclinical models showing reduced damage and accelerated repair.

Having two independent groups reach consistent conclusions strengthens the preclinical case for NMNH. However, both studies share the same limitation: neither tested oral NMNH supplementation in humans at doses available in commercial supplements.

The NAD+/NADH Ratio Question

One aspect of NMNH that receives almost no attention in supplement marketing is its effect on the NAD+/NADH ratio. This matters, because the ratio between oxidized NAD+ and reduced NADH is not just a number; it is a metabolic signal that influences how cells generate energy, handle oxidative stress, and regulate gene expression.

Liu's 2021 study documented that NMNH increases both NAD+ and NADH (the reduced form) in cells and mouse liver. This is an expected chemical consequence: NMNH feeds directly into NADH via NMNAT, and not all of that NADH will be immediately oxidized back to NAD+. The result is a transiently elevated NADH pool alongside the NAD+ elevation.

Why this matters: an elevated NADH/NAD+ ratio (sometimes called "reductive stress") has been linked to impaired mitochondrial function, increased reactive oxygen species production, and metabolic dysfunction in certain contexts. The same Liu study showed that NMNH suppressed glycolysis (the cell's glucose-burning pathway) and inhibited the TCA cycle (the mitochondrial energy production cycle). These are not pathological effects at the doses and durations tested, but they are metabolic changes that have no clear benefit for healthy adults taking a daily supplement.

NMN, by contrast, directly increases NAD+ without disproportionately raising NADH. This means NMN's effect on the NAD+/NADH ratio is more predictable and more aligned with what the supplement is intended to do: restore NAD+ levels without disrupting the redox balance that cells depend on for normal energy metabolism.

NMNH advocates may correctly point out that the body has mechanisms to rebalance the NAD+/NADH ratio over time. This is true under normal physiological conditions. Whether those mechanisms keep pace during chronic daily NMNH supplementation at 250-500 mg oral doses is an open question that has not been answered in any human study.

The Oral Bioavailability Problem

There is a critical detail in the preclinical studies that NMNH supplement marketing consistently overlooks: neither Liu nor Zapata-Pérez tested oral NMNH supplementation. Both studies administered NMNH by injection (intraperitoneal injection in mice, direct addition in cell culture). This is standard for early-stage pharmacological research, but it creates a significant gap when translating results to oral supplements.

When you swallow an NMNH capsule, the molecule must survive stomach acid, transit through the intestinal wall, survive first-pass metabolism in the liver, and reach target tissues in sufficient concentration to produce the effects seen in injection studies. At every stage, some NMNH may be oxidized back to NMN, degraded, or metabolized into other compounds. The "10-fold higher NAD+" figure from cell culture, where NMNH is applied directly to cells in a dish, says nothing about what happens when you take NMNH orally.

The 2026 Nature Metabolism study on NMN provided a surprising illustration of how oral supplementation can differ from direct administration. Christen and colleagues found that oral NMN and NR are largely converted to nicotinic acid by gut bacteria before the nicotinic acid raises systemic NAD+ levels (Christen et al., 2026, PMID: 41540253). If this same microbial conversion applies to NMNH, then much of the theoretical advantage of the reduced form may be lost in the gut before it ever reaches the bloodstream as NMNH.

This is not proof that oral NMNH is ineffective. The medRxiv preprint of the first human trial reports that oral NMNH-Ca did elevate NAD+ levels, so something is working. The question is whether oral NMNH retains enough of its preclinical potency advantage over NMN to justify the higher price and greater uncertainty, or whether the gut converts much of it into the same metabolic intermediates that NMN produces anyway.

Where NMNH Fits in the NAD+ Precursor Family

NMNH is not the only NAD+ precursor available. It exists within a family of molecules, each entering the NAD+ synthesis pathway at a different point. Understanding the family helps frame what NMNH adds (and what it does not).

Precursor	Full Name	Pathway	Human RCTs	Status
NMN	Nicotinamide mononucleotide	Salvage (direct via NMNAT)	12+	Well-validated
NR	Nicotinamide riboside	Salvage (via NRK → NMN → NAD+)	10+	Well-validated
NMNH	Dihydronicotinamide mononucleotide (reduced NMN)	Direct via NMNAT → NADH → NAD+	1 (preprint)	Early-stage
NAM	Nicotinamide (vitamin B3)	Salvage (via NAMPT → NMN → NAD+)	Many (as vitamin)	Does not sustain NAD+ chronically
NA	Nicotinic acid (niacin)	Preiss-Handler	Many (as vitamin)	Effective but causes flushing at high doses

A 2022 review of NAD+ precursors as anti-aging products noted that NMN and NR have the most developed supplement evidence base, while reduced forms like NMNH represent a newer and less characterized category (Nadeeshani et al., 2022, PMID: 35499054). The Christen 2026 Nature Metabolism trial added an unexpected wrinkle by showing that NMN and NR may both work partly through gut microbial conversion to nicotinic acid, raising the question of whether the "direct precursor" framing of NMN (and by extension NMNH) oversimplifies the actual biology.

For a detailed comparison of NMN against NR specifically, see our NMN vs NR guide. For NMN versus direct NAD+ supplements, see our NMN vs NAD guide.

The Marketing vs Evidence Gap

NMNH supplement marketing currently makes several claims that outrun the published evidence.

"10x more potent than NMN" is the most common. This figure comes from cell culture data where NMNH was applied directly to cells in a dish. It does not describe what happens when you swallow a capsule. No human study has shown 10x greater NAD+ elevation from oral NMNH versus oral NMN. The medRxiv preprint reports NAD+ elevation from NMNH-Ca but does not include a head-to-head comparison against NMN in the same trial.

"Backed by clinical studies" implies peer-reviewed, published human data. One preprint from the ingredient manufacturer does not meet the standard that "clinical studies" conveys to a consumer. NMN can accurately claim to be backed by clinical studies. NMNH cannot, as of this writing.

"Next-generation NAD+ booster" is marketing language, not a scientific classification. It implies NMNH is an upgrade from NMN. Whether it is an upgrade in humans at supplement doses remains unproven. It may turn out to be. It may also turn out to perform comparably to NMN once gut metabolism and oral bioavailability are accounted for.

None of this means NMNH is a scam or worthless. The preclinical data from two independent groups is real and promising. The appropriate frame is not "proven" or "fraudulent" but "too early to know." Consumers who choose NMNH are making a reasonable bet on preclinical promise; they should understand that it is a bet, and price their expectations accordingly.

The Human Evidence Gap: Where NMNH Stands in 2026

As of October 2026, exactly one human trial of NMNH has been conducted. A randomized, double-blind, placebo-controlled trial tested NMNH in its calcium salt form (NMNH-Ca) in healthy middle-aged and older adults. The trial was registered and results were posted as a preprint on medRxiv in August 2026. The preliminary data reported elevated NAD+ levels and no serious adverse events.

This is a preprint, not a peer-reviewed publication. It has not undergone the independent expert evaluation, statistical scrutiny, or replication assessment that peer review provides. Preprints can and do change substantially between preprint and final publication. Some are never published at all.

The trial was sponsored by EffePharm, the company behind the UthPeak branded NMNH ingredient, which is the primary commercial source of NMNH for supplement manufacturers. Industry-sponsored trials are not invalid, but they carry inherent conflicts of interest that independent replication would resolve.

Compare this to NMN's evidence base: 12+ published, peer-reviewed human RCTs spanning doses from 250 mg to 1,250 mg, conducted across the United States, Japan, India, and China, by independent research teams with no financial ties to NMN manufacturers. These include the Yoshino trial in Science (Yoshino et al., 2021, PMID: 33888596), the multicenter dose-ranging trial by Yi (Yi et al., 2023, PMID: 36482258), and the 2026 Nature Metabolism mechanistic study by Christen (Christen et al., 2026, PMID: 41540253).

A 2025 meta-analysis pooling data from 12 NMN RCTs with 513 total participants confirmed that NMN reliably elevates blood NAD+ levels in humans, with a good safety profile across the dose range (Zhang et al., 2025, PMID: 39116016). A separate 2023 review of completed NMN trials found consistent tolerability and no serious adverse events (Song et al., 2023, PMID: 37619764).

The evidence gap between NMNH and NMN is not a matter of degree. It is a difference in kind. NMN has the evidence profile of a validated supplement. NMNH has the evidence profile of a promising preclinical compound with a single unreviewed human trial.

Side-by-Side Comparison: NMNH vs NMN

Factor	NMN	NMNH
Chemical form	Oxidized	Reduced (extra hydrogen)
NAD+ pathway	NMN → NAD+ via NMNAT	NMNH → NADH → NAD+, or NMNH → NMN → NAD+
Preclinical NAD+ potency	~2x baseline (cell culture)	~10x baseline (cell culture)
Published human RCTs	12+	1 (preprint only)
Total human participants studied	500+	<100 (estimated from preprint)
Longest safety data	12+ weeks in multiple trials	Single trial duration (weeks, from preprint)
Stability	Stable in capsule/powder form	Less stable (oxidizes to NMN over time)
Typical supplement dose	250-1,000 mg	250-500 mg
Price range (30-day)	$25-$88	$35-$65
FDA status	Available as supplement (regulatory status complex; see our NMN FDA status guide)	Available as supplement (no specific FDA regulatory action)

The Stability Problem

NMNH is inherently less stable than NMN. The reduced form tends to oxidize back into NMN when exposed to air, moisture, or heat. This creates a practical problem for supplement manufacturing and storage: the NMNH you buy today may partially convert to NMN on the shelf, meaning you receive a mixture of both forms rather than pure NMNH.

The primary commercial NMNH supplier, EffePharm (marketing the ingredient as UthPeak), uses a calcium salt form (NMNH-Ca) to improve stability. Whether this formulation maintains NMNH integrity over a typical supplement shelf life (18-24 months) under real-world storage conditions (room temperature, varying humidity) is not publicly documented in peer-reviewed stability studies.

NMN degradation kinetics have been studied. A 2023 analysis found that NMN in aqueous solution degrades with temperature-dependent kinetics, and that capsule or powder formulations with proper packaging maintain stability for typical shelf-life periods (Xiang et al., 2023, PMID: 38212023). No equivalent peer-reviewed stability analysis exists for NMNH supplements.

Available NMNH Supplements on the Market

As of late 2026, the NMNH supplement market is small but growing. The major products include Double Wood Supplements NMNH (250 mg, using UthPeak branded ingredient, ~$35 for 60 capsules) and Nutricost NMNH (500 mg, ~$40 for 60 capsules). Several smaller brands offer NMNH at various doses, though supply chain verification is limited since nearly all commercial NMNH traces back to a single manufacturer (EffePharm).

This supply chain concentration is worth noting. When one company both manufactures the ingredient, conducts the clinical trial, and holds the branded ingredient patent, the independence of the evidence base is harder to evaluate. NMN, by contrast, is manufactured by dozens of suppliers worldwide, and multiple independent research teams have studied it without manufacturer funding.

NMNH vs NMN Products: A Price and Verification Comparison

Comparing specific products helps ground this discussion in what consumers actually face when deciding between NMNH and NMN. The table below lists the major available products in each category as of late 2026.

Product	Molecule	Dose/Serving	Servings	Price	$/Day	Published COA
Double Wood NMNH (UthPeak)	NMNH	250 mg	60	~$35	$0.58	Yes (on site)
Nutricost NMNH	NMNH	500 mg	30	~$40	$1.33	On request
Nutricost NMN	NMN	500 mg	30	~$27	$0.90	On request
Force Factor NMN	NMN	500 mg	30	$24.97	$0.83	No
YourHealthier NMN	NMN	500 mg	30	$29.99	$1.00	Yes (on page)
ProHealth NMN Pro	NMN	500 mg	30	~$44.95	$1.50	Yes (on page)

At comparable doses (500 mg), Nutricost NMNH costs ~$1.33/day while Nutricost NMN costs ~$0.90/day. That is roughly a 50% price premium for NMNH at the same brand. Double Wood's NMNH at 250 mg costs $0.58/day, which is competitive with budget NMN, but delivers half the dose. The premium shrinks or disappears at lower NMNH doses, but then you are also getting less of the molecule and moving further from the cell-culture concentrations where the 10-fold advantage was demonstrated.

Verification is another differentiator. Double Wood publishes third-party test results on its product page, including for the NMNH content. Nutricost's NMNH follows the same "available on request" COA policy as their NMN product. No independent lab (including SuppCo) has published a verified analysis of any NMNH supplement's actual reduced-form content versus label claims, meaning consumers cannot confirm that what is in the capsule is still NMNH rather than oxidized NMN.

12-Month Cost and Risk Analysis

Supplement decisions are long-term commitments. Here is what the numbers look like over a year for someone choosing between NMNH and NMN at equivalent target doses.

Scenario 1: NMNH at 500 mg/day (Nutricost NMNH) costs ~$480/year. You are taking a molecule with one unpublished human trial, unknown long-term safety, potential NADH accumulation effects, and unverified oral bioavailability advantage over NMN. The stability of the capsule contents over 12 months of storage is uncharacterized in peer-reviewed literature. If the NMNH in your capsule has oxidized to NMN during storage, you are paying a 50% premium for what is effectively NMN.

Scenario 2: NMN at 500 mg/day (YourHealthier NMN) costs ~$360/year. You are taking a molecule with 12+ published human RCTs, a confirmed safety profile up to 1,250 mg for multiple weeks, reliable NAD+ elevation confirmed in a Nature Metabolism study, known dose-response characteristics, and stable capsule shelf life. The COA verifies the actual NMN content.

The annual cost difference is approximately $120. The evidence difference is approximately 12 years of human research and 500+ trial participants. Whether a $120/year saving and a hypothetically higher potency precursor justifies stepping onto a thinner evidence base is a personal risk tolerance question, not a scientific one.

For consumers who are risk-tolerant, well-informed, and tracking their own NAD+ biomarkers with blood tests, experimenting with NMNH is a defensible choice. For everyone else, the standard advice applies: choose the molecule with the strongest published evidence at a verified dose. That molecule, as of October 2026, is NMN.

Should You Switch from NMN to NMNH?

If you are currently taking NMN, the case for switching to NMNH is weak as of late 2026. Here is the reasoning:

NMN's NAD+ elevation effect in humans is confirmed by multiple independent trials and a 2026 Nature Metabolism mechanistic study (Christen et al., 2026, PMID: 41540253). You know it works. You know the dose range that produces the effect. You know the safety profile at that range.

NMNH's potentially higher potency is documented in mice and cell culture, not in humans at supplement doses. The single human trial is unpublished and industry-sponsored. You do not yet know the optimal human dose, the duration of effect, or whether the preclinical potency advantage translates to oral supplementation in people. You also do not know the long-term safety profile, since no trial has evaluated NMNH use beyond a few weeks.

Switching from a well-characterized compound to a poorly characterized one because the latter showed higher potency in mice is a bet, not an evidence-based decision. If you are comfortable with that level of uncertainty and want to be an early adopter, NMNH is available and appears safe in the short term. If you want to base your supplementation on the strongest available evidence, NMN remains the clear choice. For a complete comparison of NMN against other NAD+ precursors, see our NMN vs NR guide and NMN vs NAD guide. If you are choosing between specific NMN products, our reviews of Cymbiotika, Wonderfeel, and ProHealth break down the leading options.

When NMNH Might Make Sense

There are three scenarios where NMNH could be a reasonable choice for a well-informed consumer.

You are tracking biomarkers and willing to self-experiment. If you have been taking NMN at 500+ mg daily for an extended period and have blood NAD+ testing showing modest elevation, switching to NMNH for a defined trial period (e.g., 60-90 days) while continuing to test NAD+ levels would give you personal data on whether the reduced form produces a different response for your individual biochemistry. This is self-experimentation, not evidence-based practice, but it is a rational experiment if you are already doing blood work. Track before-and-after NAD+ levels with the same lab and same test timing to control for variability.

You want hedged exposure to both forms. Some consumers alternate between NMN and NMNH on different days or weeks, reasoning that if one pathway is partially saturated, the other may provide additional benefit. There is no published data supporting or refuting this approach, but the biochemical logic is not unreasonable given that the two molecules enter the NAD+ pathway at slightly different points and the Vinten 2026 data suggests they activate different gene expression profiles (Vinten et al., 2026, PMID: 41701114).

The evidence base materially improves. If the NMNH human trial is published in a peer-reviewed journal with results confirming the preprint's findings, and if independent replication follows within a reasonable timeframe, NMNH could graduate from "promising but unproven" to "validated alternative." As of this writing, that has not happened. When it does, we will update this page.

What to Watch For: Research Milestones That Would Change This Analysis

This article's assessment of NMNH is based on the evidence available in October 2026. Several developments could shift the balance in NMNH's favor:

Peer-reviewed publication of the NMNH-Ca trial. If the medRxiv preprint survives peer review and is published in a reputable journal with its NAD+ elevation and safety data intact, NMNH's evidence profile would materially improve. The key numbers to watch: actual NAD+ fold-change versus placebo, and whether the trial includes an NMN comparator arm.

Independent replication. A second human trial, ideally conducted by a research team with no financial ties to EffePharm/UthPeak, testing oral NMNH at supplement-available doses. This is the standard that NMN has already met and that NMNH has not.

Oral bioavailability data. Pharmacokinetic studies measuring how much NMNH survives gut transit and first-pass metabolism in its reduced form versus being converted to NMN before absorption. If most oral NMNH reaches the bloodstream as NMN, the theoretical advantage of the reduced form is largely academic for supplement users.

NAD+/NADH ratio data in humans. Measurements of both NAD+ and NADH in human supplementation trials, showing whether chronic NMNH use shifts the redox ratio in ways that differ from NMN supplementation. This would address the most scientifically grounded concern about long-term NMNH use.

Until at least two of these milestones are met, the responsible position is that NMNH is a promising compound with insufficient human evidence to recommend over NMN for general NAD+ supplementation.

Frequently Asked Questions

Is NMNH better than NMN?

In cell culture and mice, NMNH raises NAD+ faster and higher than NMN. In humans, this has not been confirmed by any peer-reviewed published trial. "Better in a test tube" does not mean "better for you." NMN has 12+ human RCTs. NMNH has one preprint. Until the evidence gap closes, NMN has the stronger case.

Is NMNH safe?

The limited available data suggests NMNH is well-tolerated in short-term use. No serious adverse events were reported in the preprint of the first human trial. However, the long-term safety profile is unknown, and the cell culture data showing suppressed glycolysis, TCA cycle inhibition, and cell growth arrest (Liu et al., 2021, PMID: 33793246) warrants further investigation before long-term human use can be considered well-characterized. For NMN safety data, see our NMN side effects guide.

Can I take NMNH and NMN together?

No published study has tested this combination in humans. Since both compounds ultimately feed into the same NAD+ synthesis pathway, combining them would likely increase total NAD+ precursor input, but the optimal ratio, potential interaction effects, and whether the combination provides any advantage over either alone are entirely unknown.

Why is NMNH more expensive than NMN?

NMNH requires a more complex synthesis process and has a smaller manufacturing base (primarily EffePharm/UthPeak). Lower production volume and limited supplier competition keep prices higher. As the market matures and more manufacturers enter, prices will likely decrease.

What is UthPeak NMNH?

UthPeak is a branded NMNH ingredient manufactured by EffePharm, the same company that produces the Uthever branded NMN used in products like ProHealth NMN Pro. UthPeak is the primary (and possibly only) commercial source of NMNH available to supplement brands. EffePharm also sponsored the first human clinical trial of NMNH, which has been posted as a preprint but not yet published in a peer-reviewed journal. Double Wood Supplements and several Amazon brands use UthPeak as their NMNH source.

Is NMNH the same as NRH (reduced nicotinamide riboside)?

No. NRH and NMNH are different molecules, though both are reduced forms of NAD+ precursors. NRH is the reduced form of NR (nicotinamide riboside), while NMNH is the reduced form of NMN (nicotinamide mononucleotide). They enter the NAD+ synthesis pathway at different points. NRH has its own separate (and also limited) evidence base. The Zapata-Pérez team that studied NMNH also characterized NRH as part of a "new family of reduced NAD+ precursors" (Zapata-Pérez et al., 2021, PMID: 33724555).

Does NMNH convert to NMN in the body?

NMNH can be oxidized to NMN, which then follows the standard NMN-to-NAD+ pathway. It can also be converted directly to NADH by NMNAT. Both pathways have been observed in preclinical studies. This means that some portion of any NMNH supplement you take may simply function as NMN after conversion, particularly if the NMNH has partially oxidized during storage.

References

1. Liu Y, Luo C, Li T, et al. Reduced nicotinamide mononucleotide (NMNH) potently enhances NAD+ and suppresses glycolysis, the TCA cycle, and cell growth. J Proteome Res. 2021;20(5):2596-2606. PMID: 33793246
2. Vinten KT, et al. Reduced versus oxidized NAD+ precursors drive distinct transcriptomic responses. FASEB J. 2026. PMID: 41701114
3. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596
4. Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults. Geroscience. 2023;45(1):29-43. PMID: 36482258
5. Christen S, Cuenoud B, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026. PMID: 41540253
6. Zhang J, Poon ETC, Wong SHS, et al. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism: a systematic review with meta-analysis. Crit Rev Food Sci Nutr. 2025. PMID: 39116016
7. Song Q, Zhou X, Xu K, et al. The safety and antiaging effects of nicotinamide mononucleotide in human clinical trials: an update. Adv Nutr. 2023;14(6):1416-1435. PMID: 37619764
8. Xiang DH, et al. Degradation kinetics of β-nicotinamide mononucleotide in aqueous solution. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38212023
9. Zapata-Pérez R, Tammaro A, Schomakers BV, et al. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB J. 2021;35(4):e21456. PMID: 33724555
10. Nadeeshani H, Li J, Ying T, et al. Nicotinamide mononucleotide (NMN) as an anti-aging health product: promises and safety concerns. J Adv Res. 2022;37:267-275. PMID: 35499054

Disclaimer: This article is for informational purposes only and does not constitute medical advice. NMN and NMNH supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before beginning any supplement regimen.